

Statement of unaudited consolidated financial results for the quarter and nine months ended 31 December 2025

(Rs in Million except per share data)

Particulars	Quarter ended			Nine months ended		Year ended
	31-Dec-25 Unaudited	30-Sep-25 Unaudited	31-Dec-24 Unaudited	31-Dec-25 Unaudited	31-Dec-24 Unaudited	31-Mar-25 Audited
1 Revenue from operations	1,719.49	1,845.28	1,691.12	5,423.90	4,697.31	6,369.10
2 Other Income	84.69	102.84	76.85	276.04	242.96	330.41
3 Total Income (1+2)	1,804.18	1,948.12	1,767.97	5,699.94	4,940.27	6,699.51
4 Expenses						
(a) Cost of materials consumed	456.40	487.42	367.64	1,383.51	1,160.14	1,619.56
(b) Purchases of stock-in-trade #	0.00	0.00	-	0.00	-	-
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(42.34)	(41.75)	20.70	(23.30)	(102.40)	(100.95)
(d) Employee benefits expense (refer note iv)	412.62	393.73	345.23	1,203.48	1,047.05	1,415.42
(e) Finance costs (including exchange difference)	5.68	7.22	9.43	20.55	27.46	35.57
(f) Depreciation and amortisation expense	102.06	100.76	89.73	299.01	264.81	365.56
(g) Other expenses	399.31	405.33	405.03	1,201.83	1,104.17	1,490.71
Total Expenses	1,333.73	1,352.71	1,237.76	4,085.08	3,501.23	4,825.87
5 Profit before exceptional item and tax (3-4)	470.45	595.41	530.21	1,614.86	1,439.04	1,873.64
6 Exceptional item (charge / (credit)) (refer note viii & ix)	(112.46)	-	-	(112.46)	-	-
7 Profit before tax (5-6)	582.91	595.41	530.21	1,727.32	1,439.04	1,873.64
8 Tax expense						
Current tax	119.36	156.92	138.21	430.98	353.84	495.33
Deferred tax charge / (credit)	31.72	(8.84)	3.24	12.78	12.73	38.57
Total tax expense	151.08	148.08	141.45	443.76	366.57	533.90
9 Net profit for the period (7-8)	431.83	447.33	388.76	1,283.56	1,072.47	1,339.74
10 Other comprehensive income						
A (i) Items that will not be reclassified to profit or loss						
Remeasurements of defined benefit liability/(asset)	6.97	0.95	(0.93)	7.35	(2.86)	(6.78)
(ii) Income tax related to items that will not be reclassified to profit or loss	(1.76)	(0.27)	0.26	(1.87)	0.79	1.77
B (i) Items that will be reclassified to profit or loss						
Exchange differences in translating financial statements of foreign operations	113.80	311.39	131.42	463.30	183.69	193.23
(ii) Income tax related to items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive income	119.01	312.07	130.75	468.78	181.62	188.22
11 Total comprehensive income (9+10)	550.84	759.40	519.51	1,752.34	1,254.09	1,527.96
12 Net profit attributable to:						
Shareholders of the Company	425.00	433.27	376.47	1,257.56	1,046.34	1,311.15
Non-controlling interest	6.83	14.07	12.29	26.00	26.13	28.59
13 Other comprehensive income attributable to:						
Shareholders of the Company	118.50	312.04	130.78	468.26	181.71	188.26
Non-controlling interest	0.51	0.03	(0.03)	0.52	(0.09)	(0.04)
14 Total comprehensive income attributable to:						
Shareholders of the Company	543.50	745.30	507.25	1,725.82	1,228.05	1,499.41
Non-controlling interest	7.34	14.10	12.26	26.52	26.04	28.55
15 Paid-up Equity Share Capital (Face Value ₹ 2 each fully paid up)	223.85	223.76	223.76	223.85	223.76	223.76
16 Other equity						13,984.87
17 Earnings Per Share of ₹ 2 each (not annualized)						
(a) ₹ (Basic)	3.80	3.87	3.36	11.24	9.36	11.72
(b) ₹ (Diluted)	3.79	3.87	3.36	11.22	9.34	11.71

# Figures are below Rs. 0.01 Million, hence disclosed as Rs. 0.00



U.S. Kabra



**Advanced Enzyme Technologies Limited**

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, Near LIC Service Road, Louiswadi, Thane-400604, Maharashtra, India.

Tel No: 91-22-41703220 Fax No: +91-22-25835159

Website: www.advancedenzymes.com, Email Id :sanjay@advancedenzymes.com

**Notes:**

(i) The above unaudited consolidated financial results include the financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India), Saiganesh Enzytech Solutions Private Limited (India), Advanced Nutrazyme Private Limited (India) (w.e.f. 4 July 2025), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Sarya Labs, Inc. (w.e.f. 09 December 2024), Advanced Enzymes Europe B.V. (Netherlands) and Evoxx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".

(ii) The above unaudited consolidated financial results of the Group were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 31 January 2026. The above results have been reviewed by the statutory auditors of the Company and they have expressed an unmodified conclusion. The limited review report will be filed with stock exchanges and will be available on the Company's website. The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

(iii) The Group operates only in one business segment viz. 'manufacturing and sales of enzymes'.

(iv) The Shareholders at its Annual General meeting held on 19 August 2022 approved the Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") of the Company and its extension to the subsidiaries of the Company. National Stock Exchange of India Limited and BSE Limited (Stock Exchanges) vide their letter/e-letter dated 06 October 2022 and 18 October 2022 respectively granted its 'In-Principle' approval for listing of 2,500,000 Equity Shares of Rs. 2 each which may arise out of exercise of Options as and when exercised from time to time subject to the prescribed conditions. The Company has granted 576,000 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 12 August 2023, approved by Nomination and Remuneration Committee of the Board. The Company has further granted 512,500 options under Employee Stock Option Scheme 2022 ("ESOP Scheme 2022") on 27 March 2025, approved by Nomination and Remuneration Committee of the Board.

(v) The Group has allotted 45,650 equity shares during the quarter and nine months ended 31 December 2025 to employees under the 'Employee Stock Option Scheme 2022' ("ESOP Scheme 2022").

(vi) On 19 December 2024, the Company invested Rs 478.18 million in Advanced Enzymes Europe B.V. ('AEEBV') (wholly owned subsidiary) by way of subscription to 3,623,163 equity shares. The value per equity share is EUR 1.48 and the face value of EUR 1 per share. Pursuant to this conversion, the Company now holds 7,900,000 equity share of AEEBV and the Company continues to be 100% shareholder of AEEBV.

(vii) The Company has incorporated a new wholly owned subsidiary by name of Advanced Nutrazyme Private Limited ('ANPL'), the subsidiary received its certificate of incorporation on 4 July 2025. ANPL will be engaged in the business of sales and distribution of the Company's Nutrition and Wellness range of products.

(viii) On November 21, 2025, the Government of India notified the four Labour Codes – the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 – consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and Frequently Asked Questions (FAQs) to enable assessment of the financial impact due to changes in regulations.

The Group has assessed and disclosed the incremental impact of these changes on the basis of current remuneration structure. The current assessment is based on the best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact under "Exceptional Items" in the consolidated financial results for the period ended 31 December 2025.

The incremental impact consisting of gratuity of Rs. 45.67 million and compensated absences of Rs. 1.51 million in the consolidated financial results primarily arose due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would accordingly take necessary steps for compliance thereof and also provide appropriate accounting effect on the basis of such developments, as needed.

(ix) On 22 August 2025, United States court of appeals have directed the District of Arizona to pass the order in favour of Advanced Supplementary Technologies Corporation (U.S.A.) ("AST") wholly owned subsidiary of Advanced Enzyme USA, Inc. (U.S.A.) for the lawsuit filed by the Competitor. Based on the above direction of United States Court of Appeals and legal opinion received in the current quarter, the provision created earlier amounting to Rs. 159.64 million with respect to the mentioned lawsuit has been reversed.



By Order of the Board of Directors  
For Advanced Enzyme Technologies Limited  
CIN No.: L24200MH1989PLC051018

*M.M. Kabra*

M.M. Kabra  
Wholetime Director  
DIN : 00148294